|
1
|
Friebele JC, Peck J, Pan X, Abdel-Rasoul M
and Mayerson JL: Osteosarcoma: A Meta-analysis and review of the
literature. Am J Orthop (Belle Mead NJ). 44:547–553.
2015.PubMed/NCBI
|
|
2
|
Abarrategi A, Tornin J, Martinez-Cruzado
L, Hamilton A, Martinez-Campos E, Rodrigo JP, González MV, Baldini
N, Garcia-Castro J and Rodriguez R: Osteosarcoma: Cells-of-Origin,
cancer stem cells, and targeted therapies. Stem Cells Int.
2016:36317642016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brown HK, Tellez-Gabriel M and Heymann D:
Cancer stem cells in osteosarcoma. Cancer Lett. 386:189–195. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moore DD and Luu HH: Osteosarcoma. Cancer
Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bernthal NM, Federman N, Eilber FR, Nelson
SD, Eckardt JJ, Eilber FC and Tap WD: Long-term results (>25
years) of a randomized, prospective clinical trial evaluating
chemotherapy in patients with high-grade, operable osteosarcoma.
Cancer. 118:5888–5893. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
|
|
9
|
Zhou W, Hao M, Du X, Chen K, Wang G and
Yang J: Advances in targeted therapy for osteosarcoma. Discov Med.
17:301–307. 2014.PubMed/NCBI
|
|
10
|
Cai Y, Yu X, Hu S and Yu J: A brief review
on the mechanisms of miRNA regulation. Genomics Proteomics
Bioinformatics. 7:147–154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang L, Shrestha S, LaChaud G, Scott MA
and James AW: Review of microRNA in osteosarcoma and
chondrosarcoma. Med Oncol. 32:6132015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and Potential Targets in Osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen J, Zhou J, Chen X, Yang B, Wang D,
Yang P, He X and Li H: miRNA-449a is downregulated in osteosarcoma
and promotes cell apoptosis by targeting BCL2. Tumour Biol.
36:8221–8229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yuan G, Zhao Y, Wu D, Gao C and Jiao Z:
miRNA-20a upregulates TAK1 and increases proliferation in
osteosarcoma cells. Future Oncol. 14:461–469. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takahashi Y, Forrest AR, Maeno E,
Hashimoto T, Daub CO and Yasuda J: MiR-107 and MiR-185 can induce
cell cycle arrest in human non small cell lung cancer cell lines.
PLoS One. 4:e66772009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qadir XV, Han C, Lu D, Zhang J and Wu T:
miR-185 inhibits hepatocellular carcinoma growth by targeting the
DNMT1/PTEN/Akt pathway. Am J Pathol. 184:2355–2364. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhi Q, Zhu J, Guo X, He S, Xue X, Zhou J,
Hu B, Li H, Chen S, Zhao H and Kuang Y: Metastasis-related miR-185
is a potential prognostic biomarker for hepatocellular carcinoma in
early stage. Biomed Pharmacother. 67:393–398. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu C, Li G, Ren S, Su Z, Wang Y, Tian Y,
Liu Y and Qiu Y: miR-185-3p regulates the invasion and metastasis
of nasopharyngeal carcinoma by targeting WNT2B in vitro.
Oncol Lett. 13:2631–2636. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li G, Wang Y, Liu Y, Su Z, Liu C, Ren S,
Deng T, Huang D, Tian Y and Qiu Y: miR-185-3p regulates
nasopharyngeal carcinoma radioresistance by targeting WNT2B in
vitro. Cancer Sci. 105:1560–1568. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akram M: Mini-review on glycolysis and
cancer. J Cancer Educ. 28:454–457. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li XB, Gu JD and Zhou QH: Review of
aerobic glycolysis and its key enzymes-new targets for lung cancer
therapy. Thorac Cancer. 6:17–24. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng J: Energy metabolism of cancer:
Glycolysis versus oxidative phosphorylation (Review). Oncol Lett.
4:1151–1157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Coelho RG, Calaca IC, Celestrini DM,
Correia-Carneiro AH, Costa MM, Zancan P and Sola-Penna M:
Hexokinase and phosphofructokinase activity and intracellular
distribution correlate with aggressiveness and invasiveness of
human breast carcinoma. Oncotarget. 6:29375–29387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dai W, Wang F, Lu J, Xia Y, He L, Chen K,
Li J, Li S, Liu T, Zheng Y, et al: By reducing hexokinase 2,
resveratrol induces apoptosis in HCC cells addicted to aerobic
glycolysis and inhibits tumor growth in mice. Oncotarget.
6:13703–13717. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deng Y and Lu J: Targeting hexokinase 2 in
castration-resistant prostate cancer. Mol Cell Oncol.
2:e9744652015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu CL, Qin L, Liu HC, Candas D, Fan M and
Li JJ: Tumor cells switch to mitochondrial oxidative
phosphorylation under radiation via mTOR-mediated hexokinase II
inhibition-a Warburg-reversing effect. PLoS One. 10:e01210462015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Viticchie G, Agostini M, Lena AM, Mancini
M, Zhou H, Zolla L, Dinsdale D, Saintigny G, Melino G and Candi E:
p63 supports aerobic respiration through hexokinase II. Proc Natl
Acad Sci USA. 112:11577–11582. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou Y, Lu N, Qiao C, Ni T, Li Z, Yu B,
Guo Q and Wei L: FV-429 induces apoptosis and inhibits glycolysis
by inhibiting Akt-mediated phosphorylation of hexokinase II in
MDA-MB-231 cells. Mol Carcinog. 55:1317–1328. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Katabi MM, Chan HL, Karp SE and Batist G:
Hexokinase type II: A novel tumor-specific promoter for
gene-targeted therapy differentially expressed and regulated in
human cancer cells. Hum Gene Ther. 10:155–164. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brown RS, Goodman TM, Zasadny KR, Greenson
JK and Wahl RL: Expression of hexokinase II and Glut-1 in untreated
human breast cancer. Nucl Med Biol. 29:443–453. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Goel A, Mathupala SP and Pedersen PL:
Glucose metabolism in cancer. Evidence that demethylation events
play a role in activating type II hexokinase gene expression. J
Biol Chem. 278:15333–15340. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jin Z, Gu J, Xin X, Li Y and Wang H:
Expression of hexokinase 2 in epithelial ovarian tumors and its
clinical significance in serous ovarian cancer. Eur J Gynaecol
Onco. 35:519–524. 2014.
|
|
33
|
Peschiaroli A, Giacobbe A, Formosa A,
Markert EK, Bongiorno-Borbone L, Levine AJ, Candi E, D'Alessandro
A, Zolla L, Finazzi Agrò A and Melino G: miR-143 regulates
hexokinase 2 expression in cancer cells. Oncogene. 32:797–802.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo W, Qiu Z, Wang Z, Wang Q, Tan N, Chen
T, Chen Z, Huang S, Gu J, Li J, et al: MiR-199a-5p is negatively
associated with malignancies and regulates glycolysis and lactate
production by targeting hexokinase 2 in liver cancer. Hepatology.
62:1132–1144. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou P, Chen WG and Li XW: MicroRNA-143
acts as a tumor suppressor by targeting hexokinase 2 in human
prostate cancer. Am J Cancer Res. 5:2056–2063. 2015.PubMed/NCBI
|
|
36
|
Li LQ, Yang Y, Chen H, Zhang L, Pan D and
Xie WJ: MicroRNA-181b inhibits glycolysis in gastric cancer cells
via targeting hexokinase 2 gene. Cancer Biomark. 17:75–81. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu Y, He H, Wu B, Wen J, Guo Z, Luo Y and
Cao G: miR-125b suppresses the aerobic glycolysis of osteosarcoma
HOS cells by downregulating the expression of hexokinase-2. Xi Bao
Yu Fen Zi Mian Yi Xue Za Zhi. 33:1365–1370. 2017.(In Chinese).
PubMed/NCBI
|
|
38
|
Cates JMM: Simple staging system for
osteosarcoma performs equivalently to the AJCC and MSTS systems. J
Orthop Res. 36:2802–2808. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Garcia SN, Guedes RC and Marques MM:
Unlocking the potential of HK2 in cancer metabolism and
therapeutics. Curr Med Chem. Dec 12–2018.doi:
10.2174/0929867326666181213092652 (Epub ahead of print). View Article : Google Scholar
|
|
40
|
Gentilin E, Degli Uberti E and Zatelli MC:
Strategies to use microRNAs as therapeutic targets. Best Pract Res
Clin Endocrinol Metab. 30:629–639. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kwak PB, Iwasaki S and Tomari Y: The
microRNA pathway and cancer. Cancer Sci. 101:2309–2315. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li S, Ma Y, Hou X, Liu Y, Li K, Xu S and
Wang J: MiR-185 acts as a tumor suppressor by targeting AKT1 in
non-small cell lung cancer cells. Int J Clin Exp Pathol.
8:11854–11862. 2015.PubMed/NCBI
|
|
44
|
Tang H, Liu P, Yang L and Xie X, Ye F, Wu
M, Liu X, Chen B, Zhang L and Xie X: miR-185 suppresses tumor
proliferation by directly targeting E2F6 and DNMT1 and indirectly
upregulating BRCA1 in triple-negative breast cancer. Mol Cancer
Ther. 13:3185–3197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xia D, Li X, Niu Q, Liu X, Xu W, Ma C, Gu
H, Liu Z, Shi L, Tian X, et al: MicroRNA-185 suppresses pancreatic
cell proliferation by targeting transcriptional coactivator with
PDZ-binding motif in pancreatic cancer. Exp Ther Med. 15:657–666.
2018.PubMed/NCBI
|
|
46
|
Dong-Xu W, Jia L and Su-Juan Z:
MicroRNA-185 is a novel tumor suppressor by negatively modulating
the Wnt/β-catenin pathway in human colorectal cancer. Indian J
Cancer. 52 (Suppl 3):E182–E185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wilson JE: Isozymes of mammalian
hexokinase: Structure, subcellular localization and metabolic
function. J Exp Biol. 206:2049–2057. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Anderson M, Marayati R, Moffitt R and Yeh
JJ: Hexokinase 2 promotes tumor growth and metastasis by regulating
lactate production in pancreatic cancer. Oncotarget. 8:56081–56094.
2016.PubMed/NCBI
|
|
49
|
Katagiri M, Karasawa H, Takagi K, Nakayama
S, Yabuuchi S, Fujishima F, Naitoh T, Watanabe M, Suzuki T, Unno M
and Sasano H: Hexokinase 2 in colorectal cancer: A potent
prognostic factor associated with glycolysis, proliferation and
migration. Histol Histopathol. 32:351–360. 2017.PubMed/NCBI
|
|
50
|
Patra KC, Wang Q, Bhaskar PT, Miller L,
Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, et al:
Hexokinase 2 is required for tumor initiation and maintenance and
its systemic deletion is therapeutic in mouse models of cancer.
Cancer Cell. 24:213–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lv X, Yao L, Zhang J, Han P and Li C:
Inhibition of microRNA-155 sensitizes lung cancer cells to
irradiation via suppression of HK2-modulated glucose metabolism.
Mol Med Rep. 14:1332–1338. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lin Q, Ma L, Liu Z, Yang Z, Wang J, Liu J
and Jiang G: Targeting microRNAs: A new action mechanism of natural
compounds. Oncotarget. 8:15961–15970. 2017.PubMed/NCBI
|
|
53
|
Zhao L, Zhang Y, Liu J, Yin W, Jin D, Wang
D and Zhang W: MiR-185 inhibits cell proliferation and invasion of
non-small cell lung cancer by targeting KLF7. Oncol Res. May
1–2018.10.3727/096504018X15247341491655 (Epub ahead of print).
View Article : Google Scholar
|
|
54
|
Afshar S, Najafi R, Sedighi Pashaki A,
Sharifi M, Nikzad S, Gholami MH, Khoshghadam A, Amini R, Karimi J
and Saidijam M: MiR-185 enhances radiosensitivity of colorectal
cancer cells by targeting IGF1R and IGF2. Biomed Pharmacother.
106:763–769. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jiang CY, Ruan Y, Wang XH, Zhao W, Jiang
Q, Jing YF, Han BM, Xia SJ and Zhao FJ: MiR-185 attenuates androgen
receptor function in prostate cancer indirectly by targeting
bromodomain containing 8 isoform 2, an androgen receptor
co-activator. Mol Cell Endocrinol. 427:13–20. 2016. View Article : Google Scholar : PubMed/NCBI
|
